Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fidelity National Information Servcs Inc (FIS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Fidelity National Information Servcs IncTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Fidelity National Information Servcs Inc vs Recursion Pharmaceuticals Inc — how do they compare? Fidelity National Information Servcs Inc trades at $42.67 (market cap $22.05B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Fidelity National Information Servcs Inc is far larger — about 12.2× Recursion Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

FISRXRX
Market Cap
$22.05B$1.81B
Sector
TechnologyHealth
52-Week High
$72.77$6.79
52-Week Low
$37.72$2.84
Enterprise Value
$42.56B$1.33B
Dividend Yield
4.12%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fidelity National Information Servcs Inc

Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.

Read more on FIS

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX